Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer?

被引:43
作者
Alhamarneh, Osama [1 ]
Amarnath, Shoba M. P. [2 ]
Stafford, Nicholas D. [1 ]
Greenman, John [1 ]
机构
[1] Univ Hull, Dept Otolaryngol Head & Neck Surg, Canc Div, Postgrad Med Inst, Kingston Upon Hull HU6 7RX, N Humberside, England
[2] NCI, Expt Transplant & Immunol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2008年 / 30卷 / 02期
关键词
regulatory T cells; antitumour immunity; HNSCC; immunotherapy; TGF-beta;
D O I
10.1002/hed.20739
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Advances in the treatment modalities for head and neck squamous cell carcinoma (HNSCC) over the last 20 years involving surgery, radiotherapy, chemotherapy, and immunotherapy are not fully reflected in increases in the 5-year survival rates, mainly due to locoregional recurrences and to a lesser extent, distant metastasis. This can, in part, be attributed to the fact that HNSCC induces severe depression of a patient's immune system. Recent advances in understanding the complex host-tumor interactions have led to the identification of a distinct suppressor cell population known as regulatory T cells that play a crucial role in maintaining T-cell tolerance to self-antigens. Here, we present a critical review of our understanding of the involvement of regulatory T cells in controlling the T-cell immune response in tumor occurrence and progression in HNSCC with an emphasis on current and future immunotherapeutic approaches involving regulatory T cells. (C) 2008 Wiley Periodicals, Inc.
引用
收藏
页码:251 / 261
页数:11
相关论文
共 107 条
[1]   TGFβ signaling in health and disease [J].
Akhurst, RJ .
NATURE GENETICS, 2004, 36 (08) :790-792
[2]   Immune responses to p53 in patients with cancer:enrichment in tetramer+p53 peptide-specific T cells and regulatory T cells at tumor sites [J].
Albers, AE ;
Ferris, RL ;
Kim, GG ;
Chikamatsu, K ;
DeLeo, AB ;
Whiteside, TL .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (11) :1072-1081
[3]   Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].
Alvaro, T ;
Lejeune, M ;
Salvadó, MT ;
Bosch, R ;
García, JF ;
Jaén, J ;
Banham, AH ;
Roncador, G ;
Montalbán, C ;
Piris, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1467-1473
[4]  
AMARNATH SPV, 2006, AM ASS IMMUNOLOGISTS
[5]   Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers [J].
Badoual, C ;
Hans, S ;
Rodriguez, J ;
Peyrard, S ;
Klein, C ;
Agueznay, NE ;
Mosseri, V ;
Laccourreye, O ;
Bruneval, P ;
Fridman, WH ;
Brasnu, DF ;
Tartour, E .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :465-472
[6]   Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells [J].
Baecher-Allan, C ;
Wolf, E ;
Hafler, DA .
CLINICAL IMMUNOLOGY, 2005, 115 (01) :10-18
[7]   MHC class II expression identifies functionally distinct human regulatory T cells [J].
Baecher-Allan, Clare ;
Wolf, Elizabeth ;
Haller, David A. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (08) :4622-4631
[8]   Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells [J].
Banham, Alison H. .
TRENDS IN IMMUNOLOGY, 2006, 27 (12) :541-544
[9]   Regulatory T cells in ovarian cancer: Biology and therapeutic potential [J].
Barnett, B ;
Kryczek, I ;
Cheng, P ;
Zou, WP ;
Curiel, TJ .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 54 (06) :369-377
[10]   Lymphocyte populations in human lymph nodes.: Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vβ repertoire [J].
Battaglia, A ;
Ferrandina, G ;
Buzzonetti, A ;
Malinconico, P ;
Legge, F ;
Salutari, V ;
Scambia, G ;
Fattorossi, A .
IMMUNOLOGY, 2003, 110 (03) :304-312